Arvinas, Inc.

NasdaqGS:ARVN Stok Raporu

Piyasa değeri: US$1.5b

Arvinas Yönetim

Yönetim kriter kontrolleri 2/4

Arvinas CEO'su John Houston, Sep2017 tarihinde atandı, in görev süresi 7.17 yıldır. in toplam yıllık tazminatı $ 7.63M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.6% maaş ve 91.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.26% ine doğrudan sahiptir ve bu hisseler $ 19.46M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.8 yıl ve 5.1 yıldır.

Anahtar bilgiler

John Houston

İcra Kurulu Başkanı

US$7.6m

Toplam tazminat

CEO maaş yüzdesi8.6%
CEO görev süresi7.2yrs
CEO sahipliği1.3%
Yönetim ortalama görev süresiless than a year
Yönetim Kurulu ortalama görev süresi5.1yrs

Son yönetim güncellemeleri

Recent updates

Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause

Oct 16

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aug 02
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive

Jul 12

Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Jun 27
Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25
What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13
News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

May 05
There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Feb 24
Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Sep 09

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

CEO Tazminat Analizi

John Houston'un ücretlendirmesi Arvinas'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$309m

Jun 30 2024n/an/a

-US$323m

Mar 31 2024n/an/a

-US$355m

Dec 31 2023US$8mUS$658k

-US$367m

Sep 30 2023n/an/a

-US$295m

Jun 30 2023n/an/a

-US$298m

Mar 31 2023n/an/a

-US$301m

Dec 31 2022US$10mUS$632k

-US$282m

Sep 30 2022n/an/a

-US$253m

Jun 30 2022n/an/a

-US$233m

Mar 31 2022n/an/a

-US$213m

Dec 31 2021US$13mUS$584k

-US$191m

Sep 30 2021n/an/a

-US$180m

Jun 30 2021n/an/a

-US$164m

Mar 31 2021n/an/a

-US$139m

Dec 31 2020US$8mUS$564k

-US$119m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$86m

Mar 31 2020n/an/a

-US$78m

Dec 31 2019US$5mUS$528k

-US$70m

Sep 30 2019n/an/a

-US$65m

Jun 30 2019n/an/a

-US$173m

Mar 31 2019n/an/a

-US$179m

Dec 31 2018US$6mUS$428k

-US$240m

Sep 30 2018n/an/a

-US$233m

Jun 30 2018n/an/a

-US$114m

Mar 31 2018n/an/a

-US$98m

Dec 31 2017US$954kUS$371k

-US$29m

Tazminat ve Piyasa: John 'nin toplam tazminatı ($USD 7.63M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.34M ).

Tazminat ve Kazançlar: John 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

John Houston (64 yo)

7.2yrs

Görev süresi

US$7,627,032

Tazminat

Dr. John G. Houston, Ph.D. serves as Independent Director at NextCure, Inc. since September 10, 2020. He has been President, Chief Executive Officer and Director of Arvinas, Inc. since September 20, 2017 a...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
John Houston
Chairperson7.2yrsUS$7.63m1.26%
$ 19.5m
Ian Taylor
President of Research & Development and Chairman of Scientific Advisory Boardless than a yearUS$2.73m0.14%
$ 2.1m
Andrew Saik
CFO & Treasurerless than a yearVeri yokVeri yok
Angela Cacace
Chief Scientific Officerless than a yearVeri yok0.018%
$ 271.1k
Jared Freedberg
General Counsel & Corporate Secretaryless than a yearVeri yokVeri yok
Steve Weiss
Senior VP & Chief Human Resources Officerno dataVeri yokVeri yok
Randy Teel
Chief Business Officerless than a yearVeri yok0.021%
$ 320.5k
John Northcott
Chief Commercial Officer2.3yrsVeri yokVeri yok
Lisa Sinclair
Senior Vice President of Corporate Operations2.3yrsVeri yokVeri yok
Paul McInulty
Senior Vice President of Regulatory Affairs2.1yrsVeri yokVeri yok
Kelly Page
Senior VP & Global Head of Oncology Strategy and Program Leadership1.7yrsVeri yokVeri yok
Noah Berkowitz
Chief Medical Officerless than a yearVeri yokVeri yok

0.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: ARVN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
John Houston
Chairperson7.2yrsUS$7.63m1.26%
$ 19.5m
Ian Taylor
President of Research & Development and Chairman of Scientific Advisory Boardless than a yearUS$2.73m0.14%
$ 2.1m
Edward Kennedy
Independent Director6.3yrsUS$422.69k0.068%
$ 1.1m
Lillian Siu
Member of Scientific Advisory Board5.1yrsVeri yokVeri yok
Leslie Norwalk
Independent Director5.3yrsUS$424.99k0.0060%
$ 92.7k
Briggs W. Morrison
Lead Independent Director6.4yrsUS$441.76k0.035%
$ 541.7k
Laurie Smaldone Alsup
Independent Director5yrsUS$430.30k0.0060%
$ 92.7k
Adam Boxer
Member of Scientific Advisory Board5.1yrsVeri yokVeri yok
Lennart Mucke
Member of Scientific Advisory Board5.1yrsVeri yokVeri yok
Benjamin Neel
Member of Scientific Advisory Board5.1yrsVeri yokVeri yok
John Young
Independent Director2.3yrsUS$422.49k0.0060%
$ 92.7k
Linda Bain
Independent Director4.4yrsUS$434.99k0.0060%
$ 92.7k

5.1yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ARVN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).